

Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Independent Scientific Peer Review Panel Meeting

Assessing the Allergic Contact Dermatitis Potential of Chemicals and Products: Validation Status of New Versions and Applications of the Murine Local Lymph Node Assay (LLNA)

Consumer Product Safety Commission Headquarters
Fourth Floor Hearing Room
Bethesda Towers Building 4330 East West Highway
Bethesda, MD

Tuesday, March 4, 2008 - Thursday, March 6, 2008

TENTATIVE Agenda and Order of Business*

Tuesday, March 4, 2008

- 8:30 a.m. Opening Session**
- | | |
|--|------------------------------|
| Call to Order and Panel Introductions | Dr. Luster, Panel Chair |
| Welcome | Dr. Wind, ICCVAM Chair |
| Overview of ICCVAM Test Method | Dr. Stokes, NICEATM Director |
| Evaluation Process and Charge to the Panel | |
| Conflict of Interest Statements | Dr. Stokes |
| Overview of Agenda | Dr. Luster |
| Allergic Contact Dermatitis Current Regulatory Testing | Dr. Matheson, CPSC |
| Requirements and Hazard Classification Schemes | |
| The Traditional Murine LLNA Procedure | Dr. Matheson |
- The LLNA Limit Dose Procedure**
- Staff Presentation: Method Description and Overview
 - Panel Discussion
 - Public Comment Session: LLNA Limit Dose Procedure**
 - Action:** Panel Conclusions and Recommendations
- The Applicability Domain of the LLNA**
- Staff Presentation: Description and Overview of the draft Addendum
 - Panel Discussion
 - Public Comment Session: Applicability Domain of the LLNA**
 - Action:** Panel Conclusions and Recommendations
- 5:30 p.m. Adjourn for the Day**

** Note: This is a tentative schedule. The actual agenda may vary and it is possible that the panel may progress to the next topic earlier than scheduled, even if listed for the following day.*

Wednesday, March 5, 2008*

8:30 a.m. Call to Order and Introductions Dr. Luster

The LLNA: DA Method

Method Description and Overview Dr. Idehara, Daicel Chemical Industries
Staff Presentation: Overview of Draft Background Review Document
(BRD) and ICCVAM Recommendations
Panel Discussion
Public Comment Session: LLNA: DA Method
Action: Panel Conclusions and Recommendations

The LLNA: BrdU-FC Method

Method Description and Overview Dr. DeGeorge, MB Research Labs
Staff Presentation: Overview of Draft BRD and ICCVAM Recommendations
Panel Discussion
Public Comment Session: BrdU-FC Method
Action: Panel Conclusions and Recommendations

The LLNA: BrdU-ELISA Method

Method Description and Overview Dr. Takeyoshi, CERi - Japan
Staff Presentation: Overview of Draft BRD and ICCVAM Recommendations
Panel Discussion
Public Comment Session: BrdU-ELISA Method
Action: Panel Conclusions and Recommendations

5:30 p.m. Adjourn for the Day

Thursday, March 6, 2008*

8:30 a.m. Call to Order (10 min) Dr. Luster

Draft ICCVAM Performance Standards for LLNA

Staff Presentation of Draft Performance Standards
Panel Discussion
Public Comment Session: Draft ICCVAM Performance Standards for LLNA
Action: Panel Conclusions and Recommendations

The LLNA for Potency Determinations

Staff Presentation: Use of the LLNA for Assessing Potency
Categories for Skin Sensitization
Panel Discussion
Public Comment Session: Use of the LLNA for Potency Determinations
Action: Panel Conclusions and Recommendations

5:30 p.m. Adjourn

** Note: This is a tentative schedule. The actual agenda may vary and it is possible that the panel may progress to the next topic earlier than scheduled, even if listed for the following day.*